BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 28624679)

  • 1. Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.
    Smith GE; Sun X; Bai Y; Liu YV; Massare MJ; Pearce MB; Belser JA; Maines TR; Creager HM; Glenn GM; Flyer D; Pushko P; Levine MZ; Tumpey TM
    Virology; 2017 Sep; 509():90-97. PubMed ID: 28624679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal administration of raccoonpox virus expressing highly pathogenic avian H5N1 influenza neuraminidase is highly protective against H5N1 and seasonal influenza virus challenge.
    Kingstad-Bakke B; Kamlangdee A; Osorio JE
    Vaccine; 2015 Sep; 33(39):5155-62. PubMed ID: 26271828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection.
    Kang HJ; Chu KB; Yoon KW; Eom GD; Mao J; Kim MJ; Lee SH; Moon EK; Quan FS
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35216022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.
    Song MS; Moon HJ; Kwon HI; Pascua PN; Lee JH; Baek YH; Woo GJ; Choi J; Lee S; Yoo H; Oh I; Yoon Y; Rho JB; Sung MH; Hong SP; Kim CJ; Choi YK
    J Microbiol; 2012 Jun; 50(3):478-88. PubMed ID: 22752912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.
    Pushko P; Tretyakova I; Hidajat R; Sun X; Belser JA; Tumpey TM
    Vaccine; 2018 Jul; 36(29):4346-4353. PubMed ID: 29885769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
    Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
    J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.
    Wohlbold TJ; Nachbagauer R; Xu H; Tan GS; Hirsh A; Brokstad KA; Cox RJ; Palese P; Krammer F
    mBio; 2015 Mar; 6(2):e02556. PubMed ID: 25759506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development.
    Hong JY; Chen TH; Chen YJ; Liu CC; Jan JT; Wu SC
    Antiviral Res; 2019 Apr; 164():12-22. PubMed ID: 30738089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.